
News|Videos|November 12, 2026
Executive Conversations: Why Specialty Drug Networks Should Start Small
In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.
Advertisement
Advertisement
The first episode of Executive Conversations: The Future of Pharmaceutical Commercialization, presented by Pharmaceutical Commerce, continues with a look at how manufacturers should design distribution and dispensing networks. Host Jon Hamrick, partner at Curatio Advisors, is joined by Rena Goins, executive director, global trade at Regeneron Pharmaceuticals, and Bob Cochran, former senior director of trade relations at Incyte, who recently joined Curatio Advisors as a senior advisor.
Related to this article

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

CVS Health’s proposed separation of its retail pharmacy business from insurance and pharmacy benefit management raises a fundamental question: Will changing ownership improve pharmaceutical distribution, competition and patient access, or simply redistribute market power?

Joint clinical assessment, shifting HTA demands and pricing pressure are making launch the start of continuous evidence generation.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Advertisement
Advertisement

